Drug
Impt 514
Impt 514: highest development phase Phase 1/2, developed by Lyell Immunopharma. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1/2
- Developer
- Lyell Immunopharma
Trials
| Drug | Phase | Indication |
|---|---|---|
| IMPT-514 NCT06153095 | Phase 1/2 | Systemic Lupus Erythematosus |
Latest
No recent events.
Follow Impt 514 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.